Patent Oppositions in medicinal compounds for specific treatments industry

Explore the competitive field of medicinal compounds for specific treatments where companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top companies filing and facing patent oppositions, and the most recent patents under dispute. Stay informed on patent activity in medicinal compounds for specific treatments technology and learn how to protect your intellectual property.

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Last updated on: Apr 2, 2026
CompanyTotal Oppositions
NOVARTIS319
BOEHRINGER INGELHEIM126
AMGEN86
NOVO NORDISK79
PFIZER77
NESTLE67
NUTRICIA62
JANSSEN PHARMACEUTICA58
NESTEC55
F HOFFMANN LA ROCHE52

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the medicinal compounds for specific treatments industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the medicinal compounds for specific treatments industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Apr 2, 2026
Patent NumberTitleApplicantOpposition DateOpposition Name
Methods Of Reducing The Risk Of A Cardiovascular Event In A Subject On Statin TherapyAMARIN PHARMACEUTICALS IRELANDFeb 26, 2026DEVA HOLDING
Methods Of Reducing The Risk Of A Cardiovascular Event In A Subject On Statin TherapyAMARIN PHARMACEUTICALS IRELANDFeb 26, 2026DEVA HOLDING
Methods Of Reducing The Risk Of A Cardiovascular Event In A Subject On Statin TherapyAMARIN PHARMACEUTICALS IRELANDFeb 25, 2026ELKINGTON AND FIFE
New Use Of A Combination Of Sacubitril And ValsartanNOVARTISFeb 16, 2026ALFRED E TIEFENBACHER
New Use Of A Combination Of Sacubitril And ValsartanNOVARTISFeb 13, 2026ZENTIVA KS
Combinations Of A 4-Pyrimidinesulfamide Derivative With Active Ingredients For The Treatment Of Endothelin Related DiseasesIDORSIA PHARMACEUTICALSFeb 13, 2026ELKINGTON AND FIFE
New Use Of A Combination Of Sacubitril And ValsartanNOVARTISFeb 12, 2026DR SCHON
New Use Of A Combination Of Sacubitril And ValsartanNOVARTISFeb 10, 2026LANYON OPPOSITIONS
Heat Sterilized High Protein Compositions Comprising Whey Protein And At Least One Component Selected From (I) A Saccharide, (Ii) A Phosphate And (Iii) A CitrateNESTECFeb 6, 2026FRESENIUS KABI DEUTSCHLAND
Empagliflozin For Use In Treating Alport SyndromeBOEHRINGER INGELHEIMFeb 6, 2026GENERICS UK

To stay ahead in the competitive medicinal compounds for specific treatments industry, companies are constantly innovating. Here are the top patents facing oppositions in the medicinal compounds for specific treatments industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Apr 2, 2026
Patent NumberPublication DateTitleApplicantTotal Oppositions
Oct 12, 2022S1P Receptor Modulators For Treating Multiple SclerosisNOVARTIS23
Apr 14, 2021Methods And Compositions For Treating CancerCOUGAR BIOTECHNOLOGY22
Nov 6, 2024Dosing Regimen Associated With Long Acting Injectable Paliperidone EstersJANSSEN PHARMACEUTICA20
Jan 17, 2024Pharmaceutical Composition Comprising Glucopyranosyl Diphenylmethane Derivatives, Pharmaceutical Dosage Form Thereof, Process For Their Preparation And Uses Thereof For Improved Glycemic Control In A PatientBOEHRINGER INGELHEIM19
Oct 23, 2024New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTIS18
Oct 11, 2023New UseNOVARTIS17
Mar 8, 2023Sacubitril-Valsartan Dosage Regimen For Treating Heart FailureNOVARTIS15
Jan 16, 2019(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions ThereofCELGENE15
Mar 10, 2021Novel Antitumoral Use Of CabazitaxelAVENTIS PHARMA13
Nov 21, 2018Formulation Of Boronic Acid CompoundsTHE UNITED STATES OF AMERICA12